- Home
- GMAB vs RIVN Comparison
GMAB vs RIVN Comparison
Compare GMAB & RIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- RIVN
- Stock Information
- Founded
- GMAB 1999
- RIVN 2009
- Country
- GMAB Denmark
- RIVN United States
- Employees
- GMAB N/A
- RIVN N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- RIVN Auto Manufacturing
- Sector
- GMAB Health Care
- RIVN Consumer Discretionary
- Exchange
- GMAB Nasdaq
- RIVN Nasdaq
- Market Cap
- GMAB 17.4B
- RIVN 15.9B
- IPO Year
- GMAB N/A
- RIVN 2021
- Fundamental
- Price
- GMAB $30.42
- RIVN $15.22
- Analyst Decision
- GMAB Strong Buy
- RIVN Hold
- Analyst Count
- GMAB 6
- RIVN 20
- Target Price
- GMAB $40.40
- RIVN $14.74
- AVG Volume (30 Days)
- GMAB 2.4M
- RIVN 61.0M
- Earning Date
- GMAB 11-06-2025
- RIVN 11-04-2025
- Dividend Yield
- GMAB N/A
- RIVN N/A
- EPS Growth
- GMAB 132.41
- RIVN N/A
- EPS
- GMAB 25.10
- RIVN N/A
- Revenue
- GMAB $3,845,670,022.00
- RIVN $5,835,000,000.00
- Revenue This Year
- GMAB $24.92
- RIVN $10.72
- Revenue Next Year
- GMAB $15.97
- RIVN $31.78
- P/E Ratio
- GMAB $1.21
- RIVN N/A
- Revenue Growth
- GMAB 29.57
- RIVN 28.21
- 52 Week Low
- GMAB $17.24
- RIVN $9.55
- 52 Week High
- GMAB $33.65
- RIVN $18.13
- Technical
- Relative Strength Index (RSI)
- GMAB 56.40
- RIVN 52.93
- Support Level
- GMAB $28.08
- RIVN $14.25
- Resistance Level
- GMAB $30.78
- RIVN $18.13
- Average True Range (ATR)
- GMAB 0.68
- RIVN 1.09
- MACD
- GMAB 0.10
- RIVN 0.27
- Stochastic Oscillator
- GMAB 84.63
- RIVN 48.17
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About RIVN Rivian Automotive Inc.
Rivian Automotive Inc is an automotive manufacturer that develops and builds electric vehicles ("EVs") as well as software and services. It launches its consumer vehicle business with the R1 platform consisting of two vehicles: the R1T, and the R1S. The company has two reportable segments: Automotive, which derives the majority of revenue, and Software and Services segment. The Automotive reportable segment derives its revenues and cost of revenues from the production and sale of new EVs and the sale of regulatory credits generated by the production and sale of EVs. The Software and services reportable segment derives its revenues and cost of revenues from remarketing, vehicle repair and maintenance services, and vehicle electrical architecture and software development services.